Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2002

View Archived Issues

Incell develops oral smallpox vaccine

IND submitted for Tc-99m Hynic-Annexin V

Efficacy trends for DAC:Opioid in prevention of posthysterectomy pain

Nycomed acquires majority stake in Finnish joint venture

New data on the combination of unlabeled and I131-labeled tositumomab in NHL

Preliminary efficacy results reported at ASH meeting for zosuquidar in AML

Siplizumab combined with stem cell transplantation in refractory NHL

Good safety profile reported for ICA-17043 in sickle cell disease

Kytril available in oral solution for CINV and RINV

Valentis and GlaxoSmithKline expand GeneSwitch license

Incyte Genomics to become Incyte Corporation

New modulators of IL-8 and related chemokines identified by French researchers

GSK claims novel series of cathepsin K inhibitors for osteoporosis and other uses

Newly synthesized bradykinin B1 antagonists under study at Novartis

Series of protein kinase inhibitors covered by Novartis patent

Positive results for AC-2993 open-label study in type 2 diabetes

Internal analysis of European cetuximab colorectal cancer trial data at Merck KGaA

Drug pipeline for asthma

Good safety profile found for the antiepileptic drug levetiracetam in a community setting

Celecoxib filed for approval in Japan by Pharmacia and Yamanouchi

Shire seeks approval of Adderall XR in adults

Recent discovery of macrophage-inhibitory compounds by Sankyo researchers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...